Change in radiographic scores
| Conventional DMARDs (n = 143) | 8 mg/kg Tocilizumab (n = 157) | |
|---|---|---|
| *p<0.05, †p<0.01, ‡p<0.001. | ||
| P values were analysed with a rank transformed analysis of covariance (ANCOVA) on the change scores that included factors for baseline score and baseline disease duration. DMARDs, disease-modifying antirheumatic drugs; Tocilizumab, humanised anti-interleukin-6 receptor antibody; 95% CI, 95% confidence interval; IQR, interquartile range. | ||
| Week 28 | ||
| Total Sharp score | ||
| Mean (95% CI) | 4.5 (3.1 to 6.0) | 1.9 (1.2 to 2.6)* |
| Median (IQR) | 1.0 (0.0 to 5.0) | 0.5 (0.0 to 2.0) |
| Erosion score | ||
| Mean (95% CI) | 2.4 (1.6 to 3.2) | 0.8 (0.4 to 1.2)† |
| Median (IQR) | 0.5 (0.0 to 2.5) | 0.0 (0.0 to 1.0) |
| Joint space narrowing score | ||
| Mean (95% CI) | 2.2 (1.4 to 2.9) | 1.1 (0.7 to 1.6) |
| Median (IQR) | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 1.0) |
| Week 52 | ||
| Total Sharp score | ||
| Mean (95% CI) | 6.1 (4.2 to 8.0) | 2.3 (1.5 to 3.2)† |
| Median (IQR) | 2.5 (0.0 to 7.0) | 0.5 (0.0 to 3.0) |
| Erosion score | ||
| Mean (95% CI) | 3.2 (2.1 to 4.3) | 0.9 (0.3 to 1.4)‡ |
| Median (IQR) | 1.0 (0.0 to 3.5) | 0.0 (0.0 to 1.0) |
| Joint space narrowing score | ||
| Mean (95% CI) | 2.9 (2.0 to 3.8) | 1.5 (0.9 to 2.1)* |
| Median (IQR) | 1.0 (0.0 to 4.0) | 0.0 (0.0 to 1.7) |